TrialAnnals of the rheumatic diseases2016

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).

Gerd R Burmester et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.